WebBladder cancer (BC) is the 9th most common tumour world-wide and the most common cancer of the urinary tract . ... The molecular basis of cisplatin resistance in bladder … WebNeoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999 ;354: 533 - 540 [Erratum, Lancet 1999;354:1650 ...
Cisplatin Uses, Side Effects & Warnings - Drugs.com
WebDec 9, 2024 · Answer: Cisplatin-based chemotherapy has conventionally been the first-line (1L) treatment for patients with locally advanced and metastatic urothelial cancer (mUC) of the bladder. This treatment has resulted in overall survival (OS) benefit, with median OS of 13 to 15 months and approximately 15% long-term responses. WebFor those people, treatment with a single drug, such as gemcitabine or cisplatin, may be an option. Other drugs sometimes used alone for bladder cancer include, docetaxel, paclitaxel, doxorubicin, methotrexate, ifosfamide, and pemetrexed. sponge puff makeup
Bladder Cancer Treatment Regimens - Cancer Therapy Advisor
Cisplatin-based regimens Regimens used in the treatment of metastatic urothelial carcinoma include the following: These results suggest that PGC is a treatment option for patients with metastatic urothelial carcinoma and suggest it should be used for those with the bladder as primary origin. Pembrolizumab In the … See more INTRODUCTION Bladder cancer is the most common malignancy involving the urinary system. Urothelial (transitional cell) carcinoma is the … See more Systemic therapy for metastatic urothelial cancer is reviewed here. The use of neoadjuvant or adjuvant chemotherapy in conjunction with cystectomy and as part of a multimodality approach to preserve the bladder is discussed … See more Approximately 25 percent of patients will have muscle-invasive disease and either present with or later develop metastases. Systemic chemotherapy is the standard approach for the … See more Clinical factors A poor performance status and the presence of visceral (ie, pulmonary, liver, bone) metastases correlate with shortened survival in clinical trials. This was illustrated by an Intergroup trial that compared … See more WebHowever, bladder cancer is characterized by chemoresistance. Only modest response rates are obtained using multiagent regimens including cisplatin. These low response rates and the toxicity of these regimens limit their use to patients at highest risk. Here, we review the molecular mechanisms of cisplatin resistance. sponge rabbit snail